An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials

por Stanciu, Ioana-Miruna, Parosanu, Andreea Ioana, Nitipir, Cornelia
Publicado 2023

Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers

por Parosanu, Andreea Ioana, Baston, Catalin, Stanciu, Ioana Miruna, Parlog, Cristina Florina, Nitipir, Cornelia
Publicado 2023

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy

por Parosanu, Andreea, Stanciu, Ioana Miruna, Pirlog, Cristina, Orlov Slavu, Cristina, Cotan, Horia, Iaciu, Cristian, Popa, Ana Maria, Olaru, Mihaela, Moldoveanu, Oana, Catalin, Baston, Nitipir, Cornelia
Publicado 2022

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature

por Stanciu, Ioana-Miruna, Parosanu, Andreea Ioana, Orlov-Slavu, Cristina, Iaciu, Ion Cristian, Popa, Ana Maria, Olaru, Cristina Mihaela, Pirlog, Cristina Florina, Vrabie, Radu Constantin, Nitipir, Cornelia
Publicado 2023

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review

por Stanciu, Ioana-Miruna, Pirlog, Cristina Florina, Anghel, Andrei-Wilhelm, Parosanu, Andreea Ioana, Olaru, Cristina Mihaela, Orlov-Slavu, Cristina, Iaciu, Ion Cristian, Popa, Ana Maria, Vrabie, Radu Constantin, Nitipir, Cornelia
Publicado 2023

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma

por Parosanu, Andreea Ioana, Pirlog, Cristina Florina, Slavu, Cristina Orlov, Stanciu, Ioana Miruna, Cotan, Horia-Teodor, Vrabie, Radu Constantin, Popa, Ana-Maria, Olaru, Mihaela, Iaciu, Cristian, Bratu, Lucian Ioan, Baicoianu, Ionut Florian, Moldoveanu, Oana, Baston, Catalin, Nițipir, Cornelia
Publicado 2023